Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $460,773 - $507,473
-6,345 Reduced 56.47%
4,892 $376,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $225,201 - $270,036
-3,663 Reduced 24.58%
11,237 $821,000
Q4 2021

Feb 09, 2022

BUY
$53.63 - $62.52 $85,700 - $99,906
1,598 Added 12.01%
14,900 $929,000
Q3 2021

Oct 27, 2021

BUY
$59.17 - $69.31 $293,897 - $344,262
4,967 Added 59.59%
13,302 $787,000
Q2 2021

Jul 28, 2021

SELL
$61.91 - $67.42 $191,116 - $208,125
-3,087 Reduced 27.03%
8,335 $557,000
Q1 2021

Apr 22, 2021

SELL
$59.34 - $66.74 $158,022 - $177,728
-2,663 Reduced 18.91%
11,422 $721,000
Q4 2020

Feb 08, 2021

BUY
$57.74 - $65.43 $13,049 - $14,787
226 Added 1.63%
14,085 $873,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $67,135 - $74,395
-1,169 Reduced 7.78%
13,859 $835,000
Q2 2020

Jul 29, 2020

SELL
$54.82 - $64.09 $15,404 - $18,009
-281 Reduced 1.84%
15,028 $884,000
Q1 2020

May 01, 2020

BUY
$46.4 - $67.43 $247,822 - $360,143
5,341 Added 53.58%
15,309 $853,000
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $147,925 - $192,955
3,006 Added 43.18%
9,968 $640,000
Q3 2019

Oct 29, 2019

BUY
$42.77 - $50.71 $84,599 - $100,304
1,978 Added 39.69%
6,962 $353,000
Q2 2019

Jul 26, 2019

SELL
$44.62 - $49.34 $19,632 - $21,709
-440 Reduced 8.11%
4,984 $226,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $16,237 - $21,055
-333 Reduced 5.78%
5,424 $282,000
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $2,152 - $2,427
39 Added 0.68%
5,757 $357,000
Q4 2017

Jan 03, 2018

SELL
$59.94 - $65.35 $13,546 - $14,769
-226 Reduced 3.8%
5,718 $351,000
Q3 2017

Oct 05, 2017

BUY
$55.23 - $63.74 $328,287 - $378,870
5,944
5,944 $379,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Washington Trust Bank Portfolio

Follow Washington Trust Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Bank, based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Bank with notifications on news.